Encompass Health Corporation research snapshot
EHC AI stock analysis currently reads Encompass Health as the largest U.S. owner and operator of inpatient rehabilitation hospitals, with strong FY2025 growth, a solid Q1 2026 start, raised 2026 guidance, and a valuation near the high teens on trailing earnings. At the July 12, 2026 data cutoff, the latest verified close was $110.16 on July 10, 2026, with a market capitalization near $10.93 billion on about 99.2 million shares. The EHC AI stock forecast uses scenario ranges rather than a fixed price promise because Medicare reimbursement, labor costs, discharge growth, de novo bed openings, leverage, and earnings multiples can change the path quickly.
Current price
$110.16
Market cap
$10.93 billion verified market cap
AI score
74 / 100
Rating
Leading inpatient rehab operator with capacity growth, demographic demand, Medicare and labor risk
Trend status
Trading above the 50-day and near or slightly above the 200-day moving average after a mid-2026 rebound
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Encompass Health runs specialized inpatient rehabilitation hospitals that treat patients recovering from stroke, neurological injury, orthopedic trauma, and other complex conditions after acute care. | High |
| Moat | The moat comes from national IRF scale, clinical protocols, hospital joint ventures, certificate-of-need positioning, referral relationships, and brand recognition in rehab, but payers and local hospital systems still set pricing and volume terms. | Medium-high |
| Management | CEO Mark Tarr is executing a capacity-led strategy of de novo hospitals, bed additions, joint ventures, free cash flow reinvestment, dividends, and buybacks. The current test is opening new beds without margin dilution or leverage creep. | Medium-high |
| Financial trend | FY2025 net operating revenue was $5.935 billion and net income attributable to Encompass Health was $566.2 million. Q1 2026 revenue rose 9.0% to $1.587 billion and continuing-operations diluted EPS rose 19.6% to $1.77. | High |
| Valuation | At $110.16, EHC screens near 18.39x TTM EPS of about $5.99, 1.80x TTM sales, 4.33x book value near $25.42, 24.87x FY2025 free cash flow per share near $4.43, and a 0.67% dividend yield. | High |
| Technical trend | Price is above the 50-day moving average near $103 to $103.5 and near or slightly above the 200-day moving average near $108, still well below the 52-week high near $128. | Medium |
| Risk level | Main risks include Medicare IRF payment rules, labor and therapist staffing costs, occupancy and same-store discharge trends, construction and CON delays, competition, leverage near 2.0x, and policy or compliance shocks. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases and third-party market data agree on key financials. Return confidence is lower because reimbursement and labor assumptions can reset estimates quickly. | High data confidence |
| Investment certainty | EHC has clear business quality and growth visibility, but investment certainty depends on sustained discharges, controlled wage inflation, successful bed expansion, and a valuation that still leaves room if Medicare economics tighten. | Medium |
EHC AI stock forecast
The EHC AI stock forecast is scenario-based because inpatient rehab earnings depend on discharges, net revenue per discharge, labor costs, Medicare rates, de novo openings, occupancy, and valuation multiples. Using the $110.16 price reference, TTM EPS of about $5.99, and an audited three-year model with growth and PE assumptions of 12%/22x, 8%/18x, and 2%/13x, the mechanical outcomes are about $185 in a bullish case, $136 in a base case, and $83 in a bearish case before dividends.
$170 to $190 before dividends
More likely if same-store discharges stay positive, new hospitals ramp on plan, net revenue per discharge keeps rising, labor costs stay controlled, 2026 adjusted EPS lands near the high end of guidance, and investors pay a low-20s earnings multiple.
$125 to $145 before dividends
More likely if revenue grows near high single digits, adjusted EPS compounds near the company guidance band of about $5.89 to $6.11 for 2026, leverage stays near 2.0x, and the market keeps a high-teens earnings multiple.
$75 to $90 before dividends
More likely if Medicare payment pressure, wage inflation, weaker discharges, delayed de novos, higher interest costs, or compliance issues cut growth and compress the multiple toward the low teens.
EHC AI technical analysis
EHC AI technical analysis is constructive but not fully extended as of the July 12, 2026 data cutoff. The July 10, 2026 close was $110.16. Third-party snapshots place the 50-day moving average near $103.2 to $103.5 and the 200-day moving average near $107.8 to $108.4, with a 52-week range of about $92.77 to $127.99 and average volume near 0.9 to 1.0 million shares.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $110.16 | July 10, 2026 closing price from company IR and market data cross-checks. |
| Immediate support | $107 to $108.5 | This band brackets the 200-day moving average area and recent post-rebound support. |
| Deeper support | $102 to $104 | This area brackets the 50-day moving average near $103 to $103.5 and is the more important intermediate support zone. |
| Near resistance | $112 to $115 | Recent July highs and short-term supply sit in this band after the early-July rebound. |
| Upper resistance | $126 to $128 | This area covers the late-2025 all-time close zone near $126.47 and the 52-week high near $127.99. It is a recovery reference, not a forecast. |
| Moving averages | 50-day near $103 to $103.5, 200-day near $108 | Price above both averages supports a rebound setup, but a failure back under $108 would return the chart to a range. |
| Momentum | Rebound from June lows toward mid-range of the 52-week band | Momentum improved after the stock reclaimed short-term averages, but it is still well below the prior peak. |
| Volume | Average volume near 0.9 to 1.0 million shares | Volume confirmation matters around earnings, guidance updates, Medicare payment news, and larger buyback prints. |
| Volatility | Watch Q2 2026 earnings, Medicare IRF rules, wage trends, and bed openings | Rehab operators can gap on reimbursement language, labor shortages, discharge trends, and capacity timing. |
| Invalidation | Close below $107, then below $102 | A sustained break under the 200-day area weakens the rebound. A break under the 50-day area challenges the medium-term uptrend. |
EHC AI trading strategy
The EHC AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with discharges, net revenue per discharge, labor costs, Medicare reimbursement, de novo openings, free cash flow, leverage, and guidance.
Watch for EHC to hold $107 to $108.5 and advance through $112 to $115 with improving volume, stable or raised guidance, and no negative update on Medicare rates or labor inflation.
A failed breakout followed by a close below $107 should reduce trend confidence, especially if same-store discharge growth turns negative or wage pressure rises.
If EHC pulls back toward the 50-day average near $103 without a permanent earnings reset, compare the lower price with 2026 adjusted EPS guidance, free cash flow, leverage, discharge trends, and peer action in other post-acute and hospital operators.
Do not treat every pullback as automatically attractive if Medicare payment assumptions worsen, occupancy slips, or de novo ramps miss plans.
Track discharges, same-store discharge growth, net patient revenue per discharge, Adjusted EBITDA margin, adjusted free cash flow, bed additions, hospital openings, leverage ratio, buybacks, dividends, and IRF payment-rule updates.
Position sizing should reflect that EHC can look reasonably valued before a reimbursement or labor reset becomes visible in reported EPS.
Investment research summary
Patients and payers fund Encompass Health because complex post-acute rehab often requires intensive therapy, specialized staffing, and hospital-level medical oversight after stroke, injury, or major illness. The business converts that clinical need into net operating revenue through discharges and net revenue per discharge across a national IRF network.
The moat is strongest in scale across 174 hospitals in 39 states and Puerto Rico, clinical protocols, joint-venture hospital relationships, certificate-of-need positioning, brand recognition in inpatient rehab, and operating know-how. The moat can narrow if hospitals build competing rehab units, if therapists become scarce, or if Medicare reduces payment rates.
The thesis fails if Medicare IRF economics worsen, labor inflation outruns pricing, same-store discharges stall, new hospitals open late or underutilize beds, leverage rises as free cash flow weakens, or compliance and quality issues damage referral relationships.
Mark Tarr has emphasized capacity growth, clinical quality, free cash flow reinvestment, dividends, and share repurchases. In Q1 2026 the company opened a 49-bed hospital in Irmo, South Carolina, added 44 beds to existing facilities, and guided for eight hospital openings with 389 beds plus about 175 bed additions for full-year 2026.
Inpatient rehabilitation demand benefits from aging demographics, stroke and neurological incidence, joint replacement recovery needs, and the clinical preference for intensive rehab over lower-acuity settings when medically appropriate. The offset is that Medicare and commercial payers continuously pressure rates and utilization rules.
At $110.16, EHC already prices a durable growth story at about 18.4x trailing earnings and roughly 1.8x sales. Margin of safety improves if free cash flow funds bed growth and buybacks while leverage stays near 2.0x and the stock does not require low-20s multiple expansion to work.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $110.16 close on July 10, 2026 | Encompass Health investor stock info and market data | July 12, 2026 |
| Market capitalization | $10.93 billion, verified against 99.2 million shares | Financial rigor market-cap check plus Morningstar share count | July 12, 2026 |
| FY2025 net operating revenue | $5.935 billion | Encompass Health Q4 2025 results | July 12, 2026 |
| FY2025 net income attributable to Encompass Health | $566.2 million | Encompass Health Q4 2025 results | July 12, 2026 |
| Q1 2026 revenue and continuing-operations diluted EPS | $1.587 billion revenue and $1.77 diluted EPS | Encompass Health Q1 2026 results | July 12, 2026 |
| Q1 2026 operating metrics | 67,763 discharges, 1.6% same-store discharge growth, $22,633 net patient revenue per discharge | Encompass Health Q1 2026 results | July 12, 2026 |
| Cash and total debt | $110.5 million cash and about $2.574 billion total debt at March 31, 2026 | Encompass Health Q1 2026 balance sheet | July 12, 2026 |
| 2026 company guidance midpoint band | Revenue $6.375 to $6.470 billion, Adjusted EBITDA $1.350 to $1.380 billion, adjusted EPS $5.89 to $6.11 | Encompass Health Q1 2026 guidance update | July 12, 2026 |
| Facility footprint | 174 inpatient rehabilitation hospitals in 39 states and Puerto Rico | Encompass Health Q1 2026 company description | July 12, 2026 |
| Valuation snapshot | 18.39x PE, 1.80x sales, 4.33x book, 24.87x FCF, 0.67% dividend yield | Audited valuation math on verified price and fundamentals | July 12, 2026 |
| Technical snapshot | 50-day MA near $103 to $103.5, 200-day MA near $108, 52-week range $92.77 to $127.99 | Chartmill, Trefis, and market range cross-checks | July 12, 2026 |
This EHC AI stock analysis is an informational research tool only. It is not investment advice, a rating, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if earnings, Medicare reimbursement, labor costs, discharges, capacity plans, debt markets, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
